Indivior (NASDAQ:INDV) Hits New 52-Week High - Should You Buy?

Key Points

• Indivior PLC's stock has reached a new 52-week high, trading at $21.49, reflecting an increase in investor interest and engagement.
• Analysts have upgraded Indivior's rating, with Craig Hallum increasing its price target to $22.00, and Wall Street Zen raising it to a strong-buy rating.
• The company's recent quarterly earnings report showed an EPS of $0.51, significantly surpassing estimates, indicating strong financial performance with revenues of $302 million.

Shares of Indivior PLC (NASDAQ:INDV - Get Free Report) reached a new 52-week high on Monday . The stock traded as high as $21.49 and last traded at $21.22, with a volume of 3899789 shares. The stock had previously closed at $21.05.

Wall Street Analysts Forecast Growth

INDV has been the subject of a number of recent analyst reports. Wall Street Zen raised Indivior from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. HC Wainwright initiated coverage on Indivior in a research report on Wednesday. They set a "buy" rating and a $27.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of Indivior in a research report on Tuesday, July 22nd. They issued a "buy" rating and a $20.00 price target for the company. Finally, Craig Hallum lifted their target price on Indivior from $15.00 to $22.00 and gave the company a "buy" rating in a research note on Monday, June 30th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $19.60.

Indivior Stock Down 0.1%

The business's fifty day moving average is $15.64 and its two-hundred day moving average is $12.17. The stock has a market capitalization of $3.04 billion, a PE ratio of 35.47 and a beta of 0.74.

Indivior (NASDAQ:INDV - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.51 EPS for the quarter, topping analysts' consensus estimates of $0.26 by $0.25. Indivior had a negative return on equity of 86.28% and a net margin of 6.65%. The firm had revenue of $302.00 million during the quarter, compared to analysts' expectations of $239.43 million. Sell-side analysts expect that Indivior PLC will post 1.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of INDV. Geode Capital Management LLC increased its stake in Indivior by 1,122.6% in the second quarter. Geode Capital Management LLC now owns 1,576,915 shares of the company's stock worth $23,244,000 after purchasing an additional 1,447,939 shares during the period. ProShare Advisors LLC bought a new stake in shares of Indivior in the 2nd quarter valued at about $435,000. Acadian Asset Management LLC grew its holdings in Indivior by 124.4% in the second quarter. Acadian Asset Management LLC now owns 1,492,272 shares of the company's stock worth $21,977,000 after purchasing an additional 827,230 shares during the last quarter. Rathbones Group PLC increased its position in Indivior by 294.9% during the 2nd quarter. Rathbones Group PLC now owns 56,015 shares of the company's stock valued at $832,000 after buying an additional 41,831 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of Indivior during the second quarter valued at about $768,000. Hedge funds and other institutional investors own 60.33% of the company's stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.